Please login to the form below

Not currently logged in
Email:
Password:

Eli Lily

This page shows the latest Eli Lily news and features for those working in and with pharma, biotech and healthcare.

Biohaven gets FDA approval for migraine drug Nurtec ODT

Biohaven gets FDA approval for migraine drug Nurtec ODT

Once launched it will also have to compete with Eli Lily’s new acute migraine therapy Reyvow (lasmiditan), a first-in-class 5H-T.

Latest news

  • Nine positive opinions for new drugs at CHMP meeting Nine positive opinions for new drugs at CHMP meeting

    Another medicine for lung cancer, Portrazza (necitumumab) from Eli Lilly, was also backed by the CHMP for the treatment of squamous NSCLC.

  • Building brand strength – Part 1 Building brand strength – Part 1

    We have seen products such as Viagra, Prilosec and Lipitor along with some corporate names (eg, Eli Lily, Pfizer and Merck) nominated in our Iconic Brands survey.

  • Positive phase IV results for Zyvox

    Data from the study showed that Zyvox achieved a statistically significantly higher clinical success rate compared with vancomycin, which was first marketed as vancomycin hydrochloride by Eli Lily under the trade

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Both analysts and academics had been getting excited about the Expedition 3 trial of Eli Lilly’s solanezumab, which has been developed to target amyloid-beta - the protein that clumps together

  • Who tops the pharma list? Who tops the pharma list?

    For example, patents for Seroquel (AstraZeneca - 2011 revenues of $5.8bn), Zyprexa (Eli Lily - $4.6bn) and Concerta (J&J - $1.3bn) had all expired by May 2012.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    In July 2012, Eli Lilly opened a diabetes research centre in Shanghai. ... These include GSK's alliance with Binnopharm in Russia, Roche's partnership with Encure Pharmaceuticals to develop affordable versions of Herceptin and MabThera in India, and Eli

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...